Latest News-CliniExpert

Lilly Begins Clinical Testing of Therapies for COVID-19

INDIANAPOLIS, April 10, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today it has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID),

Data on 53 Patients Treated With Investigational Antiviral Remdesivir Through the Compassionate Use Program Published in New England Journal of Medicine

FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 10, 2020 -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from a cohort analysis of 53 patients hospitalized with severe complications of COVI

Relief Therapeutics Drug Aviptadil Enters FDA Trial at Thomas Jefferson University Hospital in Philadelphia, to treat COVID-19-Induced Acute Respiratory Distress

Geneva, Switzerland: April 9, 2020 -- RELIEF THERAPEUTICS Holding AG (SIX:RLF) “Relief” announces that its drug Aviptadil has now entered FDA clinical trials at Thomas Jefferson University Hospital in

Fujifilm Announces the Start of a Phase II Clinical Trial of its Influenza Antiviral Drug “Avigan® Tablet” for COVID-19 Patients in the U.S.

TOKYO, April 9, 2020 -- FUJIFILM Corporation (President: Kenji Sukeno) announces the initiation of a U.S. phase II clinical trial to evaluate the safety and efficacy of its influenza antiviral drug “A

Theravance Biopharma Responds to COVID-19 Pandemic by Advancing TD-0903 to Treat Hospitalized Patients with Acute Lung Injury

DUBLIN and SOUTH SAN FRANCISCO, Calif., April 9, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmace

CytoDyn Collaborating with U.K.’s Department of Health to Provide Emergency Access to Leronlimab for Severe and Critically Ill COVID-19 Patients

VANCOUVER, Washington, April 07, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 ant

Relief Therapeutics' Drug Aviptadil Enters FDA Trial at University of Miami to Treat COVID-19-Induced Respiratory Distress

Geneva, Switzerland: April 7, 2020 -- RELIEF THERAPEUTICS Holding AG (SIX:RLF) “Relief” announces that its drug Aviptadil has now entered FDA clinical trials at the University of Miami Miller School o

Genentech Provides Regulatory Update on Risdiplam for the Treatment of Spinal Muscular Atrophy (SMA)

South San Francisco, CA -- April 7, 2020 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has extended the Presc

FDA Grants Fast Track Designation to Sacituzumab Govitecan for Metastatic Urothelial Cancer

Morris Plains, N.J., April 7, 2020 -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced

FDA Clears the Way for Ridgeback Biotherapeutics to begin Human Testing of a Promising Potential Treatment for COVID-19

ATLANTA and MIAMI, April 6, 2020 /PRNewswire/ -- Ridgeback Biotherapeutics LP, a closely held biotechnology company, and Drug Innovations at Emory (DRIVE), LLC, a not-for-profit biotechnology company

FDA Clears IND for Remestemcel Use in COVID-19 ARDS Patients

Melbourne, Australia; April 6, 2020; and New York, USA; April 5, 2020 -- Mesoblast Limited (ASX:MSB; Nasdaq: MESO), global leader in cellular medicines for inflammatory diseases, today announced that

First Two Patients Enrolled in Randomized Phase 2, COVID-19 Trial with Leronlimab; Five More Severely Ill COVID-19 Patients Treated Under Emergency IND and Two Patients Have Already Extubated

VANCOUVER, Washington, April 06, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 ant